Tackling Sepsis: The Role of Advanced Panels in Fighting a Silent Killer
A patient walks into the emergency room with fever, low blood pressure, and confusion. The doctor suspects sepsis: a life-threatening condition where the body's response to infection spirals out of control. In such cases, every hour counts. For every hour treatment is delayed, the risk of death increases by up to 8%.
Yet, the challenge is clear: sepsis is not a single disease, it can be triggered by a wide variety of bacteria, fungi, and sometimes viruses. Quickly identifying the right culprit is crucial to saving lives.
What is Sepsis?
Sepsis is the body's extreme response to an infection. Instead of fighting off germs in a controlled way, the immune system overreacts, leading to tissue damage, organ failure, and, in severe cases, death.
According to the World Health Organization (WHO):
Sepsis affects 50 million people globally every year.
It is responsible for nearly 1 in 5 deaths worldwide.
Children, newborns, and patients in intensive care units (ICUs) are among the most vulnerable.
Why is Sepsis So Difficult to Manage?
The real challenge lies in detection and diagnosis.
Sepsis can be caused by a wide range of pathogens—from E. coli and Klebsiella to Staphylococcus and Candida.
Symptoms often overlap with other conditions, making it hard to pinpoint the cause quickly.
Standard blood cultures can take 24–72 hours to return results.
This delay means doctors often start patients on broad-spectrum antibiotics, which may or may not target the actual pathogen. Not only does this lower the patient's survival chances, but it also accelerates antimicrobial resistance (AMR)—one of the biggest health threats of our time.
Current Detection Methods
Blood Culture: Still the gold standard, but slow (days for results) and sometimes misses fastidious organisms.
PCR/qPCR: Detects specific pathogens with high sensitivity but usually limited to a few targets at a time.
Immunoassays: Detect host response markers but cannot always distinguish between sepsis and other inflammatory conditions.
Next-Generation Sequencing (NGS): Comprehensive but costly and not yet routine in clinical settings.
Where Do Current Technologies Fall Short?
Speed vs. breadth tradeoff – Rapid tests cover only a handful of pathogens; broad methods take too long.
High costs and infrastructure – NGS and advanced assays aren't feasible in every hospital.
Scalability – Large patient loads in ICUs and emergency wards strain current diagnostic methods.
Precision gaps – Current tests may not detect co-infections or rare but deadly organisms in time.
How AlgoBio's Sepsis Panel Can Help
At AlgoBio, we are developing a comprehensive diagnostic platform designed to address the urgent challenges of sepsis detection and treatment. Using our Tapestry technology, we are building a single-tube multiplex panel that can:
Distinguish bacterial from fungal infections in sepsis patients within hours, enabling more precise initial therapy.
Classify bacterial pathogens as Gram-positive or Gram-negative, guiding clinicians toward the right class of antibiotics early in the treatment process.
Detect critical antimicrobial resistance (AMR) genes, providing vital information to adjust therapy when standard antibiotics may fail.
The goal is simple but powerful: reduce the time to appropriate treatment and improve sepsis outcomes through rapid, targeted diagnostics.
Here's how it changes the game:
Multiplex detection: Identify bacteria, fungi, and resistance markers in one panel, instead of running multiple tests.
Speed: Results in hours, not days—supporting quicker, more precise treatment decisions.
Scalability: Algorithm-driven decoding makes it possible to test large patient volumes in resource-constrained settings.
Cost-effectiveness: Reduces the need for multiple, expensive individual tests.
Future-ready: Easy to adapt as new resistance genes or pathogens emerge.
With this approach, AlgoBio's Sepsis Panel doesn't just diagnose infection—it empowers clinicians to act faster, smarter, and more accurately, ultimately saving lives while helping curb the rise of antimicrobial resistance.
Why This Matters
With faster, more comprehensive diagnostics, doctors can:
Tailor antibiotics to the right pathogen sooner, reducing unnecessary use of broad-spectrum drugs.
Improve patient survival and outcomes.
Curb antimicrobial resistance by ensuring precise, targeted treatments.
Enable hospitals and ICUs to manage outbreaks more effectively.
Looking Ahead
Sepsis is often called the "hidden killer" because of its rapid progression and diagnostic complexity. But with innovations like AlgoBio's Sepsis Panel, we move closer to a world where a suspected sepsis case is no longer a race against time.
By combining cutting-edge molecular detection with scalable algorithms, we're building diagnostics that are not only faster and smarter but also designed for real-world hospital challenges.
Sepsis doesn't wait—and neither should diagnostics.
More Article
Tackling Sepsis: The Role of Advanced Panels in Fighting a Silent Killer
A patient walks into the emergency room with fever, low blood pressure, and confusion. The doctor suspects sepsis: a life-threatening condition where the body's response to infection spirals out of control. In such cases, every hour counts. For every hour treatment is delayed, the risk of death increases by up to 8%.
Yet, the challenge is clear: sepsis is not a single disease, it can be triggered by a wide variety of bacteria, fungi, and sometimes viruses. Quickly identifying the right culprit is crucial to saving lives.
What is Sepsis?
Sepsis is the body's extreme response to an infection. Instead of fighting off germs in a controlled way, the immune system overreacts, leading to tissue damage, organ failure, and, in severe cases, death.
According to the World Health Organization (WHO):
Sepsis affects 50 million people globally every year.
It is responsible for nearly 1 in 5 deaths worldwide.
Children, newborns, and patients in intensive care units (ICUs) are among the most vulnerable.
Why is Sepsis So Difficult to Manage?
The real challenge lies in detection and diagnosis.
Sepsis can be caused by a wide range of pathogens—from E. coli and Klebsiella to Staphylococcus and Candida.
Symptoms often overlap with other conditions, making it hard to pinpoint the cause quickly.
Standard blood cultures can take 24–72 hours to return results.
This delay means doctors often start patients on broad-spectrum antibiotics, which may or may not target the actual pathogen. Not only does this lower the patient's survival chances, but it also accelerates antimicrobial resistance (AMR)—one of the biggest health threats of our time.
Current Detection Methods
Blood Culture: Still the gold standard, but slow (days for results) and sometimes misses fastidious organisms.
PCR/qPCR: Detects specific pathogens with high sensitivity but usually limited to a few targets at a time.
Immunoassays: Detect host response markers but cannot always distinguish between sepsis and other inflammatory conditions.
Next-Generation Sequencing (NGS): Comprehensive but costly and not yet routine in clinical settings.
Where Do Current Technologies Fall Short?
Speed vs. breadth tradeoff – Rapid tests cover only a handful of pathogens; broad methods take too long.
High costs and infrastructure – NGS and advanced assays aren't feasible in every hospital.
Scalability – Large patient loads in ICUs and emergency wards strain current diagnostic methods.
Precision gaps – Current tests may not detect co-infections or rare but deadly organisms in time.
How AlgoBio's Sepsis Panel Can Help
At AlgoBio, we are developing a comprehensive diagnostic platform designed to address the urgent challenges of sepsis detection and treatment. Using our Tapestry technology, we are building a single-tube multiplex panel that can:
Distinguish bacterial from fungal infections in sepsis patients within hours, enabling more precise initial therapy.
Classify bacterial pathogens as Gram-positive or Gram-negative, guiding clinicians toward the right class of antibiotics early in the treatment process.
Detect critical antimicrobial resistance (AMR) genes, providing vital information to adjust therapy when standard antibiotics may fail.
The goal is simple but powerful: reduce the time to appropriate treatment and improve sepsis outcomes through rapid, targeted diagnostics.
Here's how it changes the game:
Multiplex detection: Identify bacteria, fungi, and resistance markers in one panel, instead of running multiple tests.
Speed: Results in hours, not days—supporting quicker, more precise treatment decisions.
Scalability: Algorithm-driven decoding makes it possible to test large patient volumes in resource-constrained settings.
Cost-effectiveness: Reduces the need for multiple, expensive individual tests.
Future-ready: Easy to adapt as new resistance genes or pathogens emerge.
With this approach, AlgoBio's Sepsis Panel doesn't just diagnose infection—it empowers clinicians to act faster, smarter, and more accurately, ultimately saving lives while helping curb the rise of antimicrobial resistance.
Why This Matters
With faster, more comprehensive diagnostics, doctors can:
Tailor antibiotics to the right pathogen sooner, reducing unnecessary use of broad-spectrum drugs.
Improve patient survival and outcomes.
Curb antimicrobial resistance by ensuring precise, targeted treatments.
Enable hospitals and ICUs to manage outbreaks more effectively.
Looking Ahead
Sepsis is often called the "hidden killer" because of its rapid progression and diagnostic complexity. But with innovations like AlgoBio's Sepsis Panel, we move closer to a world where a suspected sepsis case is no longer a race against time.
By combining cutting-edge molecular detection with scalable algorithms, we're building diagnostics that are not only faster and smarter but also designed for real-world hospital challenges.
Sepsis doesn't wait—and neither should diagnostics.
More Article
Tackling Sepsis: The Role of Advanced Panels in Fighting a Silent Killer
A patient walks into the emergency room with fever, low blood pressure, and confusion. The doctor suspects sepsis: a life-threatening condition where the body's response to infection spirals out of control. In such cases, every hour counts. For every hour treatment is delayed, the risk of death increases by up to 8%.
Yet, the challenge is clear: sepsis is not a single disease, it can be triggered by a wide variety of bacteria, fungi, and sometimes viruses. Quickly identifying the right culprit is crucial to saving lives.
What is Sepsis?
Sepsis is the body's extreme response to an infection. Instead of fighting off germs in a controlled way, the immune system overreacts, leading to tissue damage, organ failure, and, in severe cases, death.
According to the World Health Organization (WHO):
Sepsis affects 50 million people globally every year.
It is responsible for nearly 1 in 5 deaths worldwide.
Children, newborns, and patients in intensive care units (ICUs) are among the most vulnerable.
Why is Sepsis So Difficult to Manage?
The real challenge lies in detection and diagnosis.
Sepsis can be caused by a wide range of pathogens—from E. coli and Klebsiella to Staphylococcus and Candida.
Symptoms often overlap with other conditions, making it hard to pinpoint the cause quickly.
Standard blood cultures can take 24–72 hours to return results.
This delay means doctors often start patients on broad-spectrum antibiotics, which may or may not target the actual pathogen. Not only does this lower the patient's survival chances, but it also accelerates antimicrobial resistance (AMR)—one of the biggest health threats of our time.
Current Detection Methods
Blood Culture: Still the gold standard, but slow (days for results) and sometimes misses fastidious organisms.
PCR/qPCR: Detects specific pathogens with high sensitivity but usually limited to a few targets at a time.
Immunoassays: Detect host response markers but cannot always distinguish between sepsis and other inflammatory conditions.
Next-Generation Sequencing (NGS): Comprehensive but costly and not yet routine in clinical settings.
Where Do Current Technologies Fall Short?
Speed vs. breadth tradeoff – Rapid tests cover only a handful of pathogens; broad methods take too long.
High costs and infrastructure – NGS and advanced assays aren't feasible in every hospital.
Scalability – Large patient loads in ICUs and emergency wards strain current diagnostic methods.
Precision gaps – Current tests may not detect co-infections or rare but deadly organisms in time.
How AlgoBio's Sepsis Panel Can Help
At AlgoBio, we are developing a comprehensive diagnostic platform designed to address the urgent challenges of sepsis detection and treatment. Using our Tapestry technology, we are building a single-tube multiplex panel that can:
Distinguish bacterial from fungal infections in sepsis patients within hours, enabling more precise initial therapy.
Classify bacterial pathogens as Gram-positive or Gram-negative, guiding clinicians toward the right class of antibiotics early in the treatment process.
Detect critical antimicrobial resistance (AMR) genes, providing vital information to adjust therapy when standard antibiotics may fail.
The goal is simple but powerful: reduce the time to appropriate treatment and improve sepsis outcomes through rapid, targeted diagnostics.
Here's how it changes the game:
Multiplex detection: Identify bacteria, fungi, and resistance markers in one panel, instead of running multiple tests.
Speed: Results in hours, not days—supporting quicker, more precise treatment decisions.
Scalability: Algorithm-driven decoding makes it possible to test large patient volumes in resource-constrained settings.
Cost-effectiveness: Reduces the need for multiple, expensive individual tests.
Future-ready: Easy to adapt as new resistance genes or pathogens emerge.
With this approach, AlgoBio's Sepsis Panel doesn't just diagnose infection—it empowers clinicians to act faster, smarter, and more accurately, ultimately saving lives while helping curb the rise of antimicrobial resistance.
Why This Matters
With faster, more comprehensive diagnostics, doctors can:
Tailor antibiotics to the right pathogen sooner, reducing unnecessary use of broad-spectrum drugs.
Improve patient survival and outcomes.
Curb antimicrobial resistance by ensuring precise, targeted treatments.
Enable hospitals and ICUs to manage outbreaks more effectively.
Looking Ahead
Sepsis is often called the "hidden killer" because of its rapid progression and diagnostic complexity. But with innovations like AlgoBio's Sepsis Panel, we move closer to a world where a suspected sepsis case is no longer a race against time.
By combining cutting-edge molecular detection with scalable algorithms, we're building diagnostics that are not only faster and smarter but also designed for real-world hospital challenges.
Sepsis doesn't wait—and neither should diagnostics.